RU2004136276A - Комбинация ингибиторов фдэ5 с антагонистами рецепторов ангиотензина 11 - Google Patents
Комбинация ингибиторов фдэ5 с антагонистами рецепторов ангиотензина 11 Download PDFInfo
- Publication number
- RU2004136276A RU2004136276A RU2004136276/15A RU2004136276A RU2004136276A RU 2004136276 A RU2004136276 A RU 2004136276A RU 2004136276/15 A RU2004136276/15 A RU 2004136276/15A RU 2004136276 A RU2004136276 A RU 2004136276A RU 2004136276 A RU2004136276 A RU 2004136276A
- Authority
- RU
- Russia
- Prior art keywords
- hypertension
- use according
- angiotensin
- sildenafil citrate
- methyl
- Prior art date
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title claims 9
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title claims 9
- 229940127282 angiotensin receptor antagonist Drugs 0.000 title 1
- 229960002639 sildenafil citrate Drugs 0.000 claims 9
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 9
- 206010020772 Hypertension Diseases 0.000 claims 7
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 7
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 7
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 6
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 claims 6
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 6
- -1 1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d] pyrimidin-5-yl Chemical group 0.000 claims 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 2
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims 2
- 239000005480 Olmesartan Substances 0.000 claims 2
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 2
- 229960000932 candesartan Drugs 0.000 claims 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960004563 eprosartan Drugs 0.000 claims 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 2
- 229960002198 irbesartan Drugs 0.000 claims 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 2
- 229960004773 losartan Drugs 0.000 claims 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 2
- 229960005117 olmesartan Drugs 0.000 claims 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 2
- 229960001199 olmesartan medoxomil Drugs 0.000 claims 2
- 229960003310 sildenafil Drugs 0.000 claims 2
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 claims 2
- 229960005187 telmisartan Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 229960004699 valsartan Drugs 0.000 claims 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 2
- YPFZMBHKIVDSNR-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(CCOC)C(CC)=C3N=2)C(OCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 YPFZMBHKIVDSNR-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 1
- 201000004239 Secondary hypertension Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 238000009109 curative therapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000002638 palliative care Methods 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 229960000835 tadalafil Drugs 0.000 claims 1
- 229960002381 vardenafil Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0214784.1A GB0214784D0 (en) | 2002-06-26 | 2002-06-26 | Novel combination |
| GB0214784.1 | 2002-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004136276A true RU2004136276A (ru) | 2005-09-10 |
Family
ID=9939342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004136276/15A RU2004136276A (ru) | 2002-06-26 | 2003-06-16 | Комбинация ингибиторов фдэ5 с антагонистами рецепторов ангиотензина 11 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1524996A2 (https=) |
| JP (1) | JP2005531627A (https=) |
| KR (1) | KR20050013156A (https=) |
| CN (1) | CN1662257A (https=) |
| AR (1) | AR040337A1 (https=) |
| AU (1) | AU2003242895A1 (https=) |
| BR (1) | BR0312030A (https=) |
| CA (1) | CA2491002A1 (https=) |
| GB (1) | GB0214784D0 (https=) |
| GT (1) | GT200300124A (https=) |
| MX (1) | MXPA04012569A (https=) |
| NO (1) | NO20050400L (https=) |
| PA (1) | PA8575501A1 (https=) |
| PE (1) | PE20040868A1 (https=) |
| PL (1) | PL375079A1 (https=) |
| RU (1) | RU2004136276A (https=) |
| TW (1) | TW200404546A (https=) |
| UY (1) | UY27863A1 (https=) |
| WO (1) | WO2004002461A2 (https=) |
| ZA (1) | ZA200409532B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2345763C1 (ru) * | 2007-04-26 | 2009-02-10 | ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" | Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| EP2433555A3 (en) * | 2002-07-26 | 2013-01-16 | Olympus Corporation | Image processing system |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| BRPI0502411A (pt) * | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
| ES2376628T3 (es) | 2005-06-10 | 2012-03-15 | Dong-A Pharmaceutical Co., Ltd. | Agente para la prevención y el tratamiento de las enfermedades hep�?ticas que contiene un dirivado pirazolopirimidina. |
| WO2007010337A2 (de) * | 2005-07-15 | 2007-01-25 | Proxomed Medizintechnik Gmbh | Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben |
| EP1940389A2 (en) * | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US7858611B2 (en) | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| AU2007249399A1 (en) * | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US6362178B1 (en) * | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| AP2002002455A0 (en) * | 1999-10-11 | 2002-06-30 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors. |
| WO2002013798A2 (en) * | 2000-08-11 | 2002-02-21 | Pfizer Limited | Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
-
2002
- 2002-06-26 GB GBGB0214784.1A patent/GB0214784D0/en not_active Ceased
-
2003
- 2003-06-04 GT GT200300124A patent/GT200300124A/es unknown
- 2003-06-13 PA PA20038575501A patent/PA8575501A1/es unknown
- 2003-06-16 MX MXPA04012569A patent/MXPA04012569A/es unknown
- 2003-06-16 KR KR10-2004-7021041A patent/KR20050013156A/ko not_active Ceased
- 2003-06-16 RU RU2004136276/15A patent/RU2004136276A/ru not_active Application Discontinuation
- 2003-06-16 CN CN03814574XA patent/CN1662257A/zh active Pending
- 2003-06-16 WO PCT/IB2003/002657 patent/WO2004002461A2/en not_active Ceased
- 2003-06-16 JP JP2004517093A patent/JP2005531627A/ja not_active Withdrawn
- 2003-06-16 PL PL03375079A patent/PL375079A1/xx not_active Application Discontinuation
- 2003-06-16 CA CA002491002A patent/CA2491002A1/en not_active Abandoned
- 2003-06-16 BR BR0312030-9A patent/BR0312030A/pt not_active IP Right Cessation
- 2003-06-16 EP EP03761725A patent/EP1524996A2/en not_active Withdrawn
- 2003-06-16 AU AU2003242895A patent/AU2003242895A1/en not_active Abandoned
- 2003-06-20 TW TW092116851A patent/TW200404546A/zh unknown
- 2003-06-24 PE PE2003000636A patent/PE20040868A1/es not_active Application Discontinuation
- 2003-06-24 AR ARP030102252A patent/AR040337A1/es not_active Application Discontinuation
- 2003-06-24 UY UY27863A patent/UY27863A1/es not_active Application Discontinuation
-
2004
- 2004-11-25 ZA ZA200409532A patent/ZA200409532B/en unknown
-
2005
- 2005-01-25 NO NO20050400A patent/NO20050400L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2345763C1 (ru) * | 2007-04-26 | 2009-02-10 | ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" | Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200409532B (en) | 2006-06-28 |
| CN1662257A (zh) | 2005-08-31 |
| PE20040868A1 (es) | 2004-11-25 |
| MXPA04012569A (es) | 2005-04-19 |
| AU2003242895A1 (en) | 2004-01-19 |
| KR20050013156A (ko) | 2005-02-02 |
| JP2005531627A (ja) | 2005-10-20 |
| BR0312030A (pt) | 2005-03-22 |
| AR040337A1 (es) | 2005-03-30 |
| GT200300124A (es) | 2004-03-17 |
| NO20050400L (no) | 2005-03-29 |
| WO2004002461A3 (en) | 2004-05-13 |
| GB0214784D0 (en) | 2002-08-07 |
| EP1524996A2 (en) | 2005-04-27 |
| PL375079A1 (en) | 2005-11-14 |
| PA8575501A1 (es) | 2003-12-30 |
| UY27863A1 (es) | 2003-12-31 |
| WO2004002461A2 (en) | 2004-01-08 |
| TW200404546A (en) | 2004-04-01 |
| CA2491002A1 (en) | 2004-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2576548T3 (en) | USE OF sGC stimulators, sGC activators alone and in combination with PDE5 inhibitors for treating systemic sclerosis (SSc) | |
| KR100997601B1 (ko) | 카나비노이드 1 활성의 억제제로서의 아졸로피리미딘 | |
| AU767452B2 (en) | Method of treating nitrate-induced tolerance | |
| RU2008131792A (ru) | Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev | |
| AU2016370743B2 (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| ES2271221T3 (es) | Derivados imidazo-pirimidina como ligandos para receptores gaba. | |
| WO2022093856A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2016538316A5 (https=) | ||
| CA2602248A1 (en) | Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | |
| RU2004136276A (ru) | Комбинация ингибиторов фдэ5 с антагонистами рецепторов ангиотензина 11 | |
| RU2005134652A (ru) | Конденсированные n-гетероциклические соединения и их применение в качестве антагонистов рецепторов crf | |
| JP2006528229A5 (https=) | ||
| KR20110114663A (ko) | 융합된 피리미딘 | |
| JP2006522799A5 (https=) | ||
| US20190275046A1 (en) | Novel combination | |
| EP2956141A1 (en) | Novel uses | |
| JP2007526285A5 (https=) | ||
| KR20090031855A (ko) | 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과조합된 ｃ-ｓｒｃ 억제제의 용도 | |
| AU2018281131A1 (en) | Pyrazolopyrimidine PDE9 inhibitors | |
| AR044648A1 (es) | Combinaciones terapeuticas | |
| CA2529007A1 (en) | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases | |
| WO1999059584A1 (en) | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction | |
| AR040090A1 (es) | Nueva combinacion | |
| ZA200208776B (en) | Daily treatment for erectile dysfunction using a PDE5 innhibitor. | |
| JP2005531627A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20070622 |